Our study aims at defining the role of circulating microparticles in the physiopathology of two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma (SSc). Microparticles might have an prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.
Systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) are two rare and potentially life-threatening auto-immune systemic diseases. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Microparticles (MPs) are small extracellular vesicles formed from activated cells including endothelial cells and platelets. Preliminary data from our lab indicate that these MPs might play a key role in SLE and SSc physiopathology. In fact, MPs from patients with SLE aggregates with T regulator lymphocytes (LTregs) and decrease their activity, thereby promoting auto-immunity. Some works also indicate that MPs might cargo DNA to the immune system, also promoting auto-immunity. The investigators hypothesized that MPs levels might be a prognostic factor in SLE and SSc and that studying the molecular mechanisms involved could provide new therapeutic targets. Our study will recruit 100 patients with SLE or SSc followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study circulating microparticles. Fundamental research will be realized on patients' sample to study molecular mechanisms involved. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with MPs to describe their potential prognostic role. Patients will be followed at regular intervals as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same times as those drawn for clinical purposes.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
208
36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
6 ml
CHU de Bordeaux - service de rhumatologie
Bordeaux, France
Change in quantitative levels of circulating MPs between baseline and 12 months in the blood and urine samples of SLE and SSc patients
Time frame: At baseline (Day 0) and 12 months from baseline
Disease activity scores for SLE patients
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
Time frame: At baseline (Day 0) and 12 months from baseline
Disease activity scores for SSc patients
Rodnan score
Time frame: At baseline (Day 0) and 12 months from baseline
Quantification of P-selectin levels (soluble and on platelets) in the blood and urine samples of SLE and SSc patients
Time frame: At baseline (Day 0) and 12 months from baseline
Quantification of FAS-ligand levels in the blood and urine samples of SLE and SSc
Time frame: At baseline (Day 0) and 12 months from baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.